Forward Therapeutics

Executive Summary

Forward Therapeutics is a private biotechnology company focused on discovering and developing novel oral small molecule therapies for autoimmune and inflammatory diseases. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company employs a chemistry-driven approach to target key immune signaling pathways with high selectivity, aiming to improve efficacy and safety over existing treatments. With $50 million in total funding, Forward Therapeutics is in the preclinical stage, advancing its lead programs toward IND-enabling studies. The company's platform leverages deep expertise in medicinal chemistry and immunology to design molecules that modulate validated targets, potentially offering best-in-class or first-in-class oral options for patients. While still early-stage, Forward Therapeutics has the potential to address significant unmet needs in large markets such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, provided its candidates demonstrate favorable preclinical profiles and translate into clinical success.

Upcoming Catalysts (preview)

• Q3 2026Lead Program Candidate Nomination70% success
• Q1 2027Preclinical Efficacy Data Presentation at Major Conference60% success
• Q4 2026Series B Financing Round50% success